http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nautilus+Biotechnology%2C+++For%3A+Jun+17/26665955.html si-local-file:///var/storage/secattach/20260618/26665955.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nautilus+Biotechnology%2C+++For%3A+Jun+17/26665955.html Thu, 18 Jun 2026 16:06:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nautilus+Biotechnology%2C+++For%3A+Jun+17/26665955.html si-local-file:///var/storage/secattach/20260618/26665955.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nautilus+Biotechnology%2C+++For%3A+Jun+17/26665955.html Thu, 18 Jun 2026 16:06:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Nautilus+Biotechnology%2C++++++++++++++++Filed+by%3A+AH+Bio+Fund+II%2C+L.P./26606534.html si-local-file:///var/storage/secattach/20260604/26606534.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Nautilus+Biotechnology%2C++++++++++++++++Filed+by%3A+AH+Bio+Fund+II%2C+L.P./26606534.html Thu, 04 Jun 2026 16:55:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Nautilus+Biotechnology%2C++++++++++++++++Filed+by%3A+AH+Bio+Fund+II%2C+L.P./26606534.html si-local-file:///var/storage/secattach/20260604/26606534.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Nautilus+Biotechnology%2C++++++++++++++++Filed+by%3A+AH+Bio+Fund+II%2C+L.P./26606534.html Thu, 04 Jun 2026 16:55:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nautilus+Biotechnology%2C+++For%3A+Jun+02++Filed+by%3A+Andreessen+Marc+L/26606522.html si-local-file:///var/storage/secattach/20260604/26606522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nautilus+Biotechnology%2C+++For%3A+Jun+02++Filed+by%3A+Andreessen+Marc+L/26606522.html Thu, 04 Jun 2026 16:54:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nautilus+Biotechnology%2C+++For%3A+Jun+02++Filed+by%3A+Andreessen+Marc+L/26606522.html si-local-file:///var/storage/secattach/20260604/26606522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nautilus+Biotechnology%2C+++For%3A+Jun+02++Filed+by%3A+Andreessen+Marc+L/26606522.html Thu, 04 Jun 2026 16:54:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Nautilus+Biotechnology%2C+++For%3A+Dec+31/26383983.html si-local-file:///var/storage/secattach/20260428/26383983.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Nautilus+Biotechnology%2C+++For%3A+Dec+31/26383983.html Tue, 28 Apr 2026 16:11:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Nautilus+Biotechnology%2C+++For%3A+Dec+31/26383983.html si-local-file:///var/storage/secattach/20260428/26383983.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Nautilus+Biotechnology%2C+++For%3A+Dec+31/26383983.html Tue, 28 Apr 2026 16:11:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Nautilus+Biotechnology%2C++++++++++++++/26383935.html si-local-file:///var/storage/secattach/20260428/26383935.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Nautilus+Biotechnology%2C++++++++++++++/26383935.html Tue, 28 Apr 2026 16:10:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Nautilus+Biotechnology%2C++++++++++++++/26383935.html si-local-file:///var/storage/secattach/20260428/26383935.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Nautilus+Biotechnology%2C++++++++++++++/26383935.html Tue, 28 Apr 2026 16:10:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Nautilus+Biotechnology%2C+++For%3A+Jun+17/26383903.html si-local-file:///var/storage/secattach/20260428/26383903.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Nautilus+Biotechnology%2C+++For%3A+Jun+17/26383903.html Tue, 28 Apr 2026 16:09:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Nautilus+Biotechnology%2C+++For%3A+Jun+17/26383903.html si-local-file:///var/storage/secattach/20260428/26383903.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Nautilus+Biotechnology%2C+++For%3A+Jun+17/26383903.html Tue, 28 Apr 2026 16:09:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Nautilus+Biotechnology%2C+++For%3A+Mar+31/26383843.html si-local-file:///var/storage/secattach/20260428/26383843.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Nautilus+Biotechnology%2C+++For%3A+Mar+31/26383843.html Tue, 28 Apr 2026 16:08:00 -0400 NAUT O.50740961 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Nautilus+Biotechnology%2C+++For%3A+Mar+31/26383843.html si-local-file:///var/storage/secattach/20260428/26383843.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Nautilus+Biotechnology%2C+++For%3A+Mar+31/26383843.html Tue, 28 Apr 2026 16:08:00 -0400 NAUT O.50740961 http://www.streetinsider.com/Earnings/Nautilus+Biotechnology%2C+Inc.+%28NAUT%29+Tops+Q1+EPS+by+5c/26378679.html <p>Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported Q1 EPS of ($0.12), $0.05 better than the analyst estimate of ($0.17).</p><p>For earnings history and earnings-related data on Nautilus Biotechnology, Inc. (NAUT) <a href="http://www.streetinsider.com/ec_earnings.php?q=NAUT">click here</a>.</p> http://www.streetinsider.com/Earnings/Nautilus+Biotechnology%2C+Inc.+%28NAUT%29+Tops+Q1+EPS+by+5c/26378679.html Tue, 28 Apr 2026 08:00:57 -0400 NAUT http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961 http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961 http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961 http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961 http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961 http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Press+Releases/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961 http://www.streetinsider.com/Globe+Newswire/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Globe+Newswire/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961 http://www.streetinsider.com/Globe+Newswire/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Globe+Newswire/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961 http://www.streetinsider.com/Globe+Newswire/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Globe+Newswire/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961 http://www.streetinsider.com/Globe+Newswire/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html <p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Business Highlights</strong></p> <ul type="disc"><li style="text-align:justify;">Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.</li><li>Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.</li><li>Appointed Amber Faust as Vice President of Global http://www.streetinsider.com/Globe+Newswire/Nautilus+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26378526.html Tue, 28 Apr 2026 08:00:00 -0400 A.40866182 A.50209715 NAUT O.05851094 O.26458850 O.50740961